Consistent with this pre-clinical study, a recent clinical trial indicates that treatment of pancreatic cancer patients with a CCR2 antagonist (CCX872) in combination with FOLFIRINOX regimen (i.e., a combination of five chemotherapy agents) improve overall survival (102). The gene discussed is CCR2; the disease is familial pancreatic carcinoma.